Target therapy of cancer: Implementation of monoclonal antibodies and nanobodies

Human Antibodies

Volumn 18, Issue 3, 2009, Pages 81-100

  Majidi, Jafar ^a,b   Barar, Jaleh ^a,b   Baradaran, Behzad ^a   Abdolalizadeh, Jalal ^c   Omidi, Yadollah ^a,b  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antibody fragments; Cancer; Monoclonal antibodies; Nanobodies

Indexed keywords

ACETYLSALICYLIC ACID; ALEMTUZUMAB; ALPHA FETOPROTEIN; ALX 0081; ALX 0141; ALX 0681; ANTIBODY CONJUGATE; BASILIXIMAB; BEVACIZUMAB; CALICHEAMICIN; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; CHIMERIC ANTIBODY; CLOPIDOGREL; DOXORUBICIN; EPITHELIAL CELL ADHESION MOLECULE; EPRATUZUMAB; ETANERCEPT; GEMTUZUMAB OZOGAMICIN; HEPARIN; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G ANTIBODY; INFLIXIMAB; INTERLEUKIN 2; MONOCLONAL ANTIBODY; MONOPHENOL MONOOXYGENASE; NANOBODIES; PANITUMUMAB; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADD ON THERAPY; ANTIBODY AFFINITY; ANTIBODY DEPENDENT LYMPHOCYTOTOXICITY; ANTIBODY ENGINEERING; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY STRUCTURE; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; APOPTOSIS; B CELL LYMPHOMA; BACTERIOPHAGE F1; BINDING AFFINITY; BLOOD GROUP LEWIS SYSTEM; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CHIMERAPLASTY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; COMPLEMENT DEPENDENT CYTOTOXICITY; COMPLEMENT SYSTEM; CROHN DISEASE; DISEASE MODEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG SOLUBILITY; DRUG TARGETING; DRUG UPTAKE; GLAUCOMA; HEAD AND NECK CANCER; HUMAN; HUMORAL IMMUNITY; HYBRIDOMA; IMMUNOGENICITY; ISOTOPE LABELING; LUNG CANCER; NEOPLASM; NONHODGKIN LYMPHOMA; NONHUMAN; PANCREAS CANCER; PARTICLE SIZE; PHAGE DISPLAY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; REVIEW; RHEUMATOID ARTHRITIS; SOLID TUMOR; STABLE ANGINA PECTORIS; TREATMENT OUTCOME; TUMOR MODEL;

ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; HUMANS; IMMUNOTHERAPY; MICE; MUTANT CHIMERIC PROTEINS; NANOPARTICLES; NEOPLASMS; PROTEIN ENGINEERING;

EID: 70349116085     PISSN: 10932607     EISSN: None     Source Type: Journal    
DOI: 10.3233/HAB-2009-0204     Document Type: Review

References (152)

1. D.M. Parkin, Global cancer statistics in the year 2000, Lancet Oncol 2 (2001), 533-543.
2. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, T. Murray and M.J. Thun, Cancer statistics, 2008, CA Cancer J Clin 58 (2008), 71-96.
3. R.G. Panchal, Novel therapeutic strategies to selectively kill cancer cells, Biochem Pharmacol 55 (1998), 247-252.
4. V.G. Brichard and D. Lejeune, Cancer immunotherapy targeting tumour-specific antigens: towards a new therapy for minimal residual disease, Expert Opin Biol Ther 8 (2008), 951-968.
5. P.K. Wright, Targeting vesicle trafficking: an important approach to cancer chemotherapy, Recent Patents Anticancer Drug Discov 3 (2008), 137-147.
6. C. Altaner, Prodrug cancer gene therapy, Cancer Lett 270 (2008), 191-201.
7. S. Chada, K.B. Menander, D. Bocangel, J.A. Roth and R. Ramesh, Cancer targeting using tumor suppressor genes, Front Biosci 13 (2008), 1959-1967.
8. B.A. Guinn and R. Mulherkar, International progress in cancer gene therapy, Cancer Gene Ther 15 (2008), 765-775.
9. H. Revets, B.P. De and S. Muyldermans, Nanobodies as novel agents for cancer therapy, Expert Opin Biol Ther 5 (2005), 111-124.
10. Y. Omidi, J. Barar and S. Akhtar, Toxicogenomics of cationic lipid-based vectors for gene therapy: impact of microarray technology, Curr Drug Deliv, 2 (2005), 429-441.
11. G. Kohler and C. Milstein, Continuous cultures of fused cells secreting antibody of predefined specificity, Nature 256 (1975), 495-497.
12. S. Dickman, Antibodies stage a comeback in cancer treatment, Science 280 (1998), 1196-1197.
13. C. Rader and B. List, Catalytic antibodies as magic bullets, Chemistry 6 (2000), 2091-2095.
14. T. Schirrmann, L. Al-Halabi, S. Dubel and M. Hust, Production systems for recombinant antibodies, Front Biosci 13 (2008), 4576-4594.
15. G.L. Denardo, B.M. Bradt, G.R. Mirick and S.J. Denardo, Human antiglobulin response to foreign antibodies: therapeutic benefit? Cancer Immunol Immunother 52 (2003), 309-316.
16. W.Y. Hwang and J. Foote, Immunogenicity of engineered antibodies, Methods 36 (2005), 3-10.
17. S.L. Morrison, Transfectomas provide novel chimeric antibodies, Science 229 (1985), 1202-1207.
18. S.L. Morrison, New approaches to the production of mono-clonal antibodies, Science 239 (1988), G28-G48.
19. G.R. Mirick, B.M. Bradt, S.J. Denardo and G.L. Denardo, A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four letter words, Q J Nucl Med Mol Imaging 48 (2004), 251-257.
20. A.A. Kortt, O. Dolezal, B.E. Power and P.J. Hudson, Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting, Biomol Eng 18 (2001), 95-108.
21. C. Marty and R.A. Schwendener, Cytotoxic tumor targeting with scFv antibody-modified liposomes, Methods Mol Med 109 (2005), 389-402.
22. R.C. Roovers, G.A. van Dongen and P.M. en Henegouwen, Nanobodies in therapeutic applications, Curr Opin Mol Ther 9 (2007), 327-335.
23. N.L. Berinstein, Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: a review, J Clin Oncol 20 (2002), 2197-2207.
24. M.A. Morse, T.M. Clay and H.K. Lyerly, Tumor antigens, in: General Principles of Tumor Immunotherapy, H.L. Kaufman and J.D. Wolchok, eds, Springer, Dordrecht, 2007, pp. 17-32.
25. J.G. Jurcic, D.A. Mulford and D.A. Scheinberg, Monoclonal antibody therapy of cancer, in: General Principles of Tumor Immunotherapy, H.L. Kaufman and J.D. Wolchok, eds, Springer, Dordrecht, 2007, pp. 318-342.
26. V.R. Juarez-Gonzalez, L. Riano-Umbarila, V. Quintero-Hernandez, T. Olamendi-Portugal, M. Ortiz-Leon, E. Ortiz, L.D. Possani and B. Becerril, Directed evolution, phage display and combination of evolved mutants: a strategy to recover the neutralization properties of the scFv version of BCF2 a neutralizing monoclonal antibody specific to scorpion toxin Cn2, J Mol Biol 346 (2005), 1287-1297.
27. C. Rader, D.A. Cheresh and C.F. Barbas, III, A phage display approach for rapid antibody humanization: designed combinatorial V gene libraries, Proc Natl Acad Sci U S A 95 (1998), 8910-8915.
28. H. Modjtahedi, Monoclonal Antibodies as Therapeutic Agents: Advances and Challenges, Iranian Journal of Immunology 2 (2005), 3-20.
29. M. Harris, Monoclonal antibodies as therapeutic agents for cancer, Lancet Oncol 5 (2004), 292-302.
30. M. Mehren, G.P. Adams and L.M. Weiner, Monoclonal Antibody Therapy for Cancer, Annual Reviews in Medicine 54 (2003), 343-369.
31. G.P. Adams and L.M. Weiner, Monoclonal antibody therapy of cancer, Nat Biotechnol, 23 (2005), 1147-1157.
32. R.O. Dillman, Antibodies as cytotoxic therapy, J Clin Oncol 12 (1994), 1497-1515.
33. L. Fong and E.J. Small, Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of im-munomodulatory antibodies for cancer treatment, J Clin On-col 26 (2008), 5275-5283.
34. D. Arsene, M.P. Galais, K. Bouhier-Leporrier and J.M. Reimund, Recent developments in colorectal cancer treatment by monoclonal antibodies, Expert Opin Biol Ther 6 (2006), 1175-1192.
35. B.I. Rini, Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions, Clin Cancer Res 13 (2007), 1098-1106.
36. D.L. Wheeler, S. Huang, T.J. Kruser, M.M. Nechrebecki, E.A. Armstrong, S. Benavente, V. Gondi, K.T. Hsu and P.M. Harari, Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members, Oncogene 27 (2008), 3944-3956.
37. R. Bartsch, C. Wenzel, C.C. Zielinski and G.G. Steger, HER-2-positive breast cancer: hope beyond trastuzumab, Bio-Drugs 21 (2007), 69-77.
38. T.A. Waldmann, R. Levy and B.S. Coller, Emerging Therapies: Spectrum of Applications of Monoclonal Antibody Therapy, Hematology Am Soc Hematol Educ Program (2000), 394-408.
39. S.A. Eccles, Monoclonal antibodies targeting cancer: 'magic bullets' or just the trigger? Breast Cancer Res 3 (2001), 86-90.
40. H.J. Lenz, Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events, Oncology (Williston Park) 20 (2006), 5-13.
41. D.L. Nielsen, M. Andersson and C. Kamby, HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors, Cancer Treat Rev (2008).
42. S. Sathornsumetee and J.N. Rich, Antiangiogenic therapy in malignant glioma: promise and challenge, Curr Pharm Des 13 (2007), 3545-3558. (Pubitemid 350238925)
43. K. Kawakami, O. Nakajima, R. Morishita and R. Nagai, Targeted anticancer immunotoxins and cytotoxic agents with direct killing moieties, Scientific World Journal 6 (2006), 781-790.
44. D.E. Milenic and M.W. Brechbiel, Targeting of radioisotopes for cancer therapy, Cancer Biol Ther 3 (2004), 361-370.
45. J.F. Dijoseph, A. Popplewell, S. Tickle, H. Ladyman, A. Lawson, A. Kunz, K. Khandke, D.C. Armellino, E.R. Boghaert, P. Hamann, K. Zinkewich-Peotti, S. Stephens, N. Weir and N.K. Damle, Antibody-targeted chemotherapy of B-cell lym-phoma using calicheamicin conjugated to murine or humanized antibody against CD22, Cancer Immunol Immunother 54 (2005), 11-24.
46. M.S. Tallman, Monoclonal antibody therapies in leukemias, Semin Hematol 39 (2002), 12-19.
47. B. Baradaran, A. Zavaran Hosseini, J. Majidi, S. Farajnia, J. Barar, Z.M. Hassan, J. Abdolalizadeh and Y. Omidi, Development and characterization of monoclonal antibodies against human epidermal growth factor receptor in Balb/c mice, Hum Antibodies 18 (2009), in press.
48. D.J. King, Applications and Engineering of Monoclonal Antibodies, Taylor & Francis Ltd., London, 2005, pp. 1-26.
49. R.M. Sharkey and D.M. Goldenberg, Targeted therapy of cancer: new prospects for antibodies and immunoconjugates, CA Cancer J Clin 56 (2006), 226-243.
50. K. Andreassen, G. Bredholt, U. Moens, S. Bendiksen, G. Kauric and O.P. Rekvig, T cell lines specific for polyomavirus T-antigen recognize T-antigen complexed with nucleosomes: a molecular basis for anti-DNA antibody production, Eur J Immunol 29 (1999), 2715-2728.
51. P.J. Hudson and C. Souriau, Engineered antibodies, Nat Med 9 (2003), 129-134.
52. P. Holliger and P.J. Hudson, Engineered antibody fragments and the rise of single domains, Nat Biotechnol 23 (2005), 1126-1136.
53. G.P. Adams, R. Schier, A.M. McCall, H.H. Simmons, E.M. Horak, R.K. Alpaugh, J.D. Marks and L.M. Weiner, High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules, Cancer Res 61 (2001), 4750-4755.
54. M. Raghavan and P.J. Bjorkman, Fc receptors and their interactions with immunoglobulins, Annu Rev Cell Dev Biol 12 (1996), 181-220.
55. M. Sakagami, Y. Omidi, L. Campbell, L.E. Kandalaft, C.J. Morris, J. Barar and M. Gumbleton, Expression and transport functionality of FcRn within rat alveolar epithelium: a study in primary cell culture and in the isolated perfused lung, Pharm Res 23 (2006), 270-279.
56. T. Takizawa, C.L. Anderson and J.M. Robinson, A novel Fc gamma R-defined, IgG-containing organelle in placental endothelium, J Immunol 175 (2005), 2331-2339.
57. N. Fischer and O. Leger, Bispecific antibodies: molecules that enable novel therapeutic strategies, Pathobiology 74 (2007), 3-14.
58. D. Muller and R.E. Kontermann, Recombinant bispecific antibodies for cellular cancer immunotherapy, Curr Opin Mol Ther 9 (2007), 319-326.
59. D. Das and M.R. Suresh, Producing bispecific and bifunc-tional antibodies, Methods Mol Med 109 (2005), 329-346.
60. L. Shen, P.M. Guyre, C.L. Anderson and M.W. Fanger, Heteroantibody- mediated cytotoxicity: antibody to the high affinity Fc receptor for IgG mediates cytotoxicity by human monocytes that is enhanced by interferon-gamma and is not blocked by human IgG, J Immunol 137 (1986), 3378-3382.
61. P.M. Guyre, R.F. Graziano, B.A. Vance, P.M. Morganelli and M.W. Fanger, Monoclonal antibodies that bind to distinct epitopes on Fc gamma RI are able to trigger receptor function, J Immunol 143 (1989), 1650-1655.
62. C. Liu, E.J. Gosselin and P.M. Guyre, Fc gamma RII on human B cells can mediate enhanced antigen presentation, Cell Immunol 167 (1996), 188-194.
63. T. Keler, R.F. Graziano, A. Mandal, P.K. Wallace, J. Fisher, P.M. Guyre, M.W. Fanger and Y.M. Deo, Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells, Cancer Res 57 (1997), 4008-4014.
64. R. Repp, T. Valerius, G. Wieland, W. Becker, H. Steininger, Y. Deo, G. Helm, M. Gramatzki, J.G. van de Winkel, N. Lang and, G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210), J Hematother 4 (1995), 415-421.
65. F.H. Valone, P.A. Kaufman, P.M. Guyre, L.D. Lewis, V. Memoli, M.S. Ernstoff, W. Wells, R. Barth, Y. Deo, J. Fisher and, Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that overexpresses HER-2/neu, J Hematother 4 (1995), 471-475.
66. Y. Cao and L. Lam, Bispecific antibody conjugates in therapeutics, Adv Drug Deliv Rev, 55 (2003), 171-197.
67. R.E. Kontermann, Recombinant bispecific antibodies for cancer therapy, Acta Pharmacol Sin 26 (2005), 1-9.
68. L.J. Holt, C. Enever, R.M. de Wildt and I.M. Tomlinson, The use of recombinant antibodies in proteomics, Curr Opin Biotechnol 11 (2000), 445-449.
69. L. Riechmann, M. Clark, H. Waldmann and G. Winter, Reshaping human antibodies for therapy, Nature 332 (1988), 323-327.
70. X.D. Yang, X.C. Jia, J.R. Corvalan, P. Wang and C.G. Davis, Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy, Crit Rev Oncol Hematol 38 (2001), 17-23.
71. L.L. Green, M.C. Hardy, C.E. Maynard-Currie, H. Tsuda, D.M. Louie, M.J. Mendez, H. Abderrahim, M. Noguchi, D.H. Smith, Y. Zeng and, Antigen-specific human mono-clonal antibodies from mice engineered with human Ig heavy and light chain YACs, Nat Genet 7 (1994), 13-21.
72. P. Boerner, R. Lafond, W.Z. Lu, P. Brams and I. Royston, Production of antigen-specific human monoclonal antibodies from in vitro-primed human splenocytes, J Immunol 147 (1991), 86-95.
73. O. Nolan and R. O'Kennedy, Bifunctional antibodies: concept, production and applications, Biochim Biophys Acta 1040 (1990), 1-11.
74. K. Kronenberger, E. Nossner, B. Frankenberger, U. Wahl, M. Dreyling, M. Hallek and R. Mocikat, A polyvalent cellular vaccine induces T-cell responses against specific self-antigens overexpressed in chronic lymphocytic B-cell leukemia, J Immunother 31 (2008), 723-730.
75. D. Kozbor, J.C. Roder, T.H. Chang, Z. Steplewski and H. Ko-prowski, Human anti-tetanus toxoid monoclonal antibody secreted by EBV-transformed human B cells fused with murine myeloma, Hybridoma 1 (1982), 323-328.
76. J.C. Roder, S.P. Cole and D. Kozbor, The EBV-hybridoma technique, Methods Enzymol 121 (1986), 140-167.
77. B. Gustafsson and J. Hinkula, Antibody production of a human EBV-transformed B cell line and its heterohybridoma and trioma cell line descendants in different culture systems, Hum Antibodies Hybridomas 5 (1994), 98-104.
78. A. Darveau, M.C. Chevrier, S. Neron, R. Delage and R. Lemieux, Efficient preparation of human monoclon-al antibody-secreting heterohybridomas using peripheral B lymphocytes cultured in the CD40 system, J Immunol Methods 159 (1993), 139-143.
79. F. Bombil, J.P. Kints, J.M. Scheiff, H. Bazin and D. Latinne, A promising model of primary human immunization in human-scid mouse, Immunobiology 195 (1996), 360-375.
80. M.A. Duchosal, S.A. Eming, P.J. McConahey and F.J. Dixon, The hu-PBL-SCID mouse model. Long-term human serologic evolution associated with the xenogeneic transfer of human peripheral blood leukocytes into SCID mice, Cell Immunol 139 (1992), 468-477.
81. R. Carlsson, C. Martensson, S. Kalliomaki, M. Ohlin and C.A. Borrebaeck, Human peripheral blood lymphocytes transplanted into SCID mice constitute an in vivo culture system exhibiting several parameters found in a normal humoral immune response and are a source of immunocytes for the production of human monoclonal antibodies, J Immunol 148 (1992), 1065-1071.
82. J. Sandhu, B. Shpitz, S. Gallinger and N. Hozumi, Human primary immune response in SCID mice engrafted with human peripheral blood lymphocytes, J Immunol, 152 (1994), 3806-3813.
83. D.J. Jackson and B.M. Kumpel, Optimisation of human anti-tetanus toxoid antibody responses and location of human cells in SCID mice transplanted with human peripheral blood leucocytes, Hum Antibodies 8 (1997), 181-188.
84. W. Walker and G. Gallagher, The in vivo production of spe-cific human antibodies by vaccination of human-PBL-SCID mice, Immunology 83 (1994), 163-170.
85. R. Bazin, M.C. Chevrier, R. Delage and R. Lemieux, Evidence for restricted diversity of antigen-specific human antibodies in immunized hu-PBL-SCID mice, Hum Antibodies Hybridomas 7 (1996), 129-134.
86. S. Naito, Y. Okada, M. Takahashi, H. Kato, M. Taneichi, Y. Ami, Y. Suzaki, T. Oka, K. Okuma, K. Morokuma, H. Onodera, M. Inoue, Y. Takahashi, S. Yamazaki, H. Kimura, K. Komuro and T. Uchida, Anti-tetanus toxoid antibody production and protection against lethal doses of tetanus toxin in hu-PBL-SCID mice, Int Arch Allergy Immunol 123 (2000), 149-154.
87. M.D. Melamed, K.M. Thompson, T. Gibson and N.C. Hughes-Jones, Requirements for the establishment of hetero-hybridomas secreting monoclonal human antibody to rhesus (D) blood group antigen, J Immunol Methods 104 (1987), 245-251.
88. M.C. Mowry, M. Meagher, L. Smith, J. Marks and A. Sub-ramanian, Production and purification of a chimeric mon-oclonal antibody against botulinum neurotoxin serotype A, Protein Expr Purif 37 (2004), 399-408.
89. N. Lonberg, Human monoclonal antibodies from transgenic mice, Handb Exp Pharmacol (2008), 69-97.
90. N. Lonberg, L.D. Taylor, F.A. Harding, M. Trounstine, K.M. Higgins, S.R. Schramm, C.C. Kuo, R. Mashayekh, K. Wymore, J.G. McCabe and, Antigen-specific human antibodies from mice comprising four distinct genetic modifications, Nature 368 (1994), 856-859.
91. L.L. Green, Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies, J Immunol Methods 231 (1999), 11-23.
92. I. Ishida, K. Tomizuka, H. Yoshida, T. Tahara, N. Takahashi, A. Ohguma, S. Tanaka, M. Umehashi, H. Maeda, C. Nozaki, E. Halk and N. Lonberg, Production of human monoclonal and polyclonal antibodies in TransChromo animals, Cloning Stem Cells 4 (2002), 91-102.
93. J.D. Marks, A.D. Griffiths, M. Malmqvist, T.P. Clackson, J.M. Bye and G. Winter, By-passing immunization: building high affinity human antibodies by chain shuffling, Biotechnology (N Y) 10 (1992), 779-783.
94. C. Rader and C.F. Barbas, III, Phage display of combinatorial antibody libraries, Curr Opin Biotechnol 8 (1997), 503-508.
95. N. Lonberg, Fully human antibodies from transgenic mouse and phage display platforms, Curr Opin Immunol 20 (2008), 450-459.
96. S.E. Matsumoto, M. Yamashita, Y. Katakura, Y. Aiba, K. Tomimatsu, S. Kabayama, K. Teruya and S. Shirahata, A rapid and efficient strategy to generate antigen-specific human monoclonal antibody by in vitro immunization and the phage display method, J Immunol Methods 332 (2008), 2-9.
97. W.D. Huse, L. Sastry, S.A. Iverson, A.S. Kang, M. ting-Mees, D.R. Burton, S.J. Benkovic and R.A. Lerner, Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda, Science 246 (1989), 1275-1281.
98. J. McCafferty, A.D. Griffiths, G. Winter and D.J. Chiswell, Phage antibodies: filamentous phage displaying antibody variable domains, Nature 348 (1990), 552-554.
99. K. Hertveldt, T. Belien and G. Volckaert, General M13 phage display: M13 phage display in identification and characterization of protein-protein interactions, Methods Mol Biol 502 (2009), 321-339.
100. M. Hust and S. Dubel, Phage display vectors for the in vitro generation of human antibody fragments, Methods Mol Biol 295 (2005), 71-96.
101. M.A. Clark, Overview of antibody phage-display technology and Its applications, in: Antibody Phage Display, P.M. O'Brien and R. Aitken, eds, Human Press, New Jersey,2003, pp. 39-58.
102. M. Russel, H.B. Lowman and T. Clackson, Introduction to phage biology and phage display, in: Phage Display, T. Clackson and H.B. Lowman, eds, Oxford University Press, New York, 2004, pp. 1-26.
103. G. Winter and C. Milstein, Man-made antibodies, Nature 349 (1991), 293-299.
104. G. Winter, A.D. Griffiths, R.E. Hawkins and H.R. Hoogen-boom, Making antibodies by phage display technology, Annu Rev Immunol 12 (1994), 433-455.
105. D.R. Burton and C.F. Barbas, III, Human antibodies from combinatorial libraries, Adv Immunol 57 (1994), 191-280.
106. A. Pini and L. Bracci, Phage display of antibody fragments, Curr Protein Pept Sci 1 (2000), 155-169.
107. R.E. Hawkins, S.J. Russell and G. Winter, Selection of phage antibodies by binding affinity. Mimicking affinity maturation, J Mol Biol 226 (1992), 889-896.
108. J.D. Watkins, G. Beuerlein, H. Wu, P.R. McFadden, J.D. Pancook and W.D. Huse, Discovery of human antibodies to cell surface antigens by capture lift screening of phage-expressed antibody libraries, Anal Biochem 256 (1998), 169-177.
109. M. Duenas and C.A. Borrebaeck, Clonal selection and am-plification of phage displayed antibodies by linking antigen recognition and phage replication, Biotechnology (N Y) 12 (1994), 999-1002.
110. S. Jung, K.M. Arndt, K.M. Muller and A. Pluckthun, Selectively infective phage (SIP) technology: scope and limitations, J Immunol Methods 231 (1999), 93-104.
111. K.M. Arndt, S. Jung, C. Krebber and A. Pluckthun, Selectively infective phage technology, Methods Enzymol 328 (2000), 364-388.
112. R.K. Oldham and R.O. Dillman, Monoclonal antibodies in cancer therapy: 25 years of progress, J Clin Oncol 26 (2008), 1774-1777.
113. G. Metro, M. Mottolese and A. Fabi, HER-2-positive metastatic breast cancer: trastuzumab and beyond, Expert Opin Pharmacother 9 (2008), 2583-2601.
114. S.L. Moulder and C.L. Arteaga, A Phase I/II Trial of trastuzumab and gefitinib in patients with Metastatic Breast Cancer that overexpresses HER2/neu (ErbB-2), Clin Breast Cancer 4 (2003), 142-145.
115. D.J. Kerr, Targeting angiogenesis in cancer: clinical development of bevacizumab, Nat Clin Pract Oncol 1 (2004), 39-43.
116. P.L. McCormack and S.J. Keam, Bevacizumab: a review of its use in metastatic colorectal cancer, Drugs 68 (2008), 487-506.
117. M. Cohenuram and M.W. Saif, Panitumumab the first fully human monoclonal antibody: from the bench to the clinic, Anticancer Drugs 18 (2007), 7-15.
118. F. Grossi and M. Aita, Bevacizumab and non-small-cell lung cancer: starving the enemy to survive, Expert Opin Biol Ther 7 (2007), 1107-1119.
119. P. Ichhpujani, A. Ramasubramanian, S. Kaushik and S.S. Pandav, Bevacizumab in glaucoma: a review, Can J Oph-thalmol 42 (2007), 812-815.
120. D.F. James and T.J. Kipps, Alemtuzumab in chronic lympho-cytic leukemia, Future Oncol 3 (2007), 29-42.
121. G. Ciancio, G.W. Burke, M.E. Warque and J. Miller, Efficacy of alemtuzumab in organ transplantation: current clinical status, BioDrugs 20 (2006), 85-92.
122. A. Ziada, A. Barqawi, L.M. Glode, M. Varella-Garcia, F. Crighton, S. Majeski, M. Rosenblum, M. Kane, L. Chen and E.D. Crawford, The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial, Prostate 60 (2004), 332-337.
123. C.G. Azzoli, L.M. Krug, V.A. Miller, M.G. Kris and R. Mass, Trastuzumab in the treatment of non-small cell lung cancer, Semin Oncol 29 (2002), 59-65.
124. C.S. Zent, T.G. Call, T.D. Shanafelt, R.C. Tschumper, D.F. Jelinek, D.A. Bowen, C.R. Secreto, B.R. Laplant, B.F. Kabat and N.E. Kay, Early treatment of high-risk chronic lympho-cytic leukemia with alemtuzumab and rituximab, Cancer 113 (2008), 2110-2118.
125. M. Saleh, Monoclonal antibody therapy of non-Hodgkin's lymphoma: the Rituximab story, J Med Assoc Ga 92 (2003), 39-46.
126. C.A. White, Rituximab immunotherapy for non-Hodgkin's lymphoma, Cancer Biother Radiopharm 14 (1999), 241-250.
127. F. Giuliani and G. Colucci, Cetuximab in colon cancer, Int J Biol Markers 22 (2007), S62-S70.
128. E.S. Kim, E.E. Vokes and M.S. Kies, Cetuximab in cancers of the lung and head & neck, Semin Oncol 31 (2004), 61-67.
129. H.Q. Xiong, A. Rosenberg, A. LoBuglio, W. Schmidt, R.A. Wolff, J. Deutsch, M. Needle and J.L. Abbruzzese, Cetux-imab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial, J Clin Oncol 22 (2004), 2610-2616.
130. C.S. Hendrix, L.C. de and R.O. Dillman, Radioimmunother-apy for non-Hodgkin's lymphoma with yttrium 90 ibritu-momab tiuxetan, Clin J Oncol Nurs 6 (2002), 144-148.
131. A.J. Davies, A review of tositumomab and I(131) tositu-momab radioimmunotherapy for the treatment of follicular lymphoma, Expert Opin Biol Ther 5 (2005), 577-588.
132. R.R. Furman, M. Coleman and J.P. Leonard, Epratuzumab in non-Hodgkin's lymphomas, Curr Treat Options Oncol 5 (2004), 283-288.
133. D.R. Couriel, K. Hicks, S. Giralt and R.E. Champlin, Role of tumor necrosis factor-alpha inhibition with inflixiMAB in cancer therapy and hematopoietic stem cell transplantation, Curr Opin Oncol 12 (2000), 582-587.
134. E.R. Brown, K.A. Charles, S.A. Hoare, R.L. Rye, D.I. Jo-drell, R.E. Aird, R. Vora, U. Prabhakar, M. Nakada, R.E. Cor-ringham, M. DeWitte, C. Sturgeon, D. Propper, F.R. Balkwill and J.F. Smyth, A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer, Ann Oncol 19 (2008), 1340-1346.
135. O. Boyman, C.D. Surh and J. Sprent, Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease, Expert Opin Biol Ther 6 (2006), 1323-1331.
136. S. Madhusudan, M. Foster, S.R. Muthuramalingam, J.P. Braybrooke, S. Wilner, K. Kaur, C. Han, S. Hoare, F. Balk-will, D.C. Talbot, T.S. Ganesan and A.L. Harris, A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer, Clin Cancer Res 10 (2004), 6528-6534.
137. C. Hamers-Casterman, T. Atarhouch, S. Muyldermans, G. Robinson, C. Hamers, E.B. Songa, N. Bendahman and R. Hamers, Naturally occurring antibodies devoid of light chains, Nature 363 (1993), 446-448.
138. S. Muyldermans and M. Lauwereys, Unique single-domain antigen binding fragments derived from naturally occurring camel heavy-chain antibodies, J Mol Recognit, 12 (1999), 131-140.
139. E. De Genst, D. Saerens, S. Muyldermans and K. Conrath, Antibody repertoire development in camelids, Dev Comp Immunol 30 (2006), 187-198.
140. E. De Genst, K. Silence, K. Decanniere, K. Conrath, R. Loris, J. Kinne, S. Muyldermans and L. Wyns, Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies, Proc Natl Acad Sci U S A 103 (2006), 4586-4591.
141. A. Desmyter, T.R. Transue, M.A. Ghahroudi, M.H. Thi, F. Poortmans, R. Hamers, S. Muyldermans and L. Wyns, Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme, Nat Struct Biol 3 (1996), 803-811.
142. S. Muyldermans, T.N. Baral, V.C. Retamozzo, B.P. De, G.E. De, J. Kinne, H. Leonhardt, S. Magez, V.K. Nguyen, H. Revets, U. Rothbauer, B. Stijlemans, S. Tillib, U. Wernery, L. Wyns, G. Hassanzadeh-Ghassabeh and D. Saerens, Camelid immunoglobulins and nanobody technology, Vet Immunol Immunopathol 128 (2009), 178-183.
143. M.M. Harmsen and H.J. de Haard, Properties, production, and applications of camelid single-domain antibody fragments, Appl Microbiol Biotechnol 77 (2007), 13-22.
144. B. Stijlemans, K. Conrath, V. Cortez-Retamozo, X.H. Van, L. Wyns, P. Senter, H. Revets, B.P. De, S. Muyldermans and S. Magez, Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies. African trypanosomes as paradigm, J Biol Chem 279 (2004), 1256-1261.
145. M. Lauwereys, G.M. Arbabi, A. Desmyter, J. Kinne, W. Holzer, G.E. De, L. Wyns and S. Muyldermans, Potent enzyme inhibitors derived from dromedary heavy-chain antibodies, EMBO J 17 (1998), 3512-3520.
146. L. Huang, L.O. Gainkam, V. Caveliers, C. Vanhove, M. Keyaerts, B.P. De, A. Bossuyt, H. Revets and T. La-houtte, SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression, Mol Imaging Biol 10 (2008), 167-175.
147. R.C. Roovers, T. Laeremans, L. Huang, T.S. De, A.J. Verkleij, H. Revets, H.J. de Haard and P.M. van Bergen en Henegouwen, Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies, Cancer Immunol Immunother 56 (2007), 303-317.
148. U. Rothbauer, K. Zolghadr, S. Tillib, D. Nowak, L. Scher-melleh, A. Gahl, N. Backmann, K. Conrath, S. Muylder-mans, M.C. Cardoso and H. Leonhardt, Targeting and tracing antigens in live cells with fluorescent nanobodies, Nat Methods 3 (2006), 887-889.
149. J.M. Reichert, Monoclonal antibodies as innovative therapeutics, Curr Pharm Biotechnol, 9 (2008), 423-430.
150. J.M. Reichert, C.J. Rosensweig, L.B. Faden and M.C. De-witz, Monoclonal antibody successes in the clinic, Nat Biotechnol 23 (2005), 1073-1078.
151. S.M. Moghimi, Recent developments in polymeric nanopar-ticle engineering and their applications in experimental and clinical oncology, Anticancer Agents Med Chem 6 (2006), 553-561.
152. D.H. Palmer, L.S. Young and V. Mautner, Cancer gene-therapy: clinical trials, Trends Biotechnol 24 (2006), 76-82.